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1. Introduction
Esophageal cancer, the 8th most common cancer and 6th leading cause of cancer deaths
worldwide (Jemal et al., 2010), remains an invasive disease with 5-year overall survival rates
(SRs) of only 20% in the USA (Daly, et al., 1996), 13% in UK (http://info.cancerresearchuk.org/
cancerstats/types/oesophagus/survival/), and less than 10% in most parts of Europe (Keighley
2003). In Japan, an updated nationwide survey (http://ganjoho.jp/public/statistics/backnum‐
ber/2011_en.html) has demonstrated 5-year SRs of 33% for all esophageal cancers and 43% for
resected cases, while in the USA, the survivals have improved to 42% in the past decade (Rice
et al., 2009). Still, these statistics consistently confirm that survival remains disappointing, with
less than half of all patients surviving at 5 years. Where the disease appears resectable and
patients are sufficiently fit, surgery remains the mainstay of curative therapy. However, the
overall poor prognosis with esophagectomies has led to the investigation of multimodal
therapies in order to improve the treatment results. Among these, preoperative chemo-
radiotherapy (CRT) (neoadjuvant CRT) has been developed and proved promising; nonethe‐
less, morbidity and mortality have increased. What this means is that any improvement in
survival rates of complete resection or local disease control by neoadjuvant CRT happens at
the expense of greater toxicity. Several meta-analysis have elucidated that preoperative CRT
significantly (Fiorica et al., 2004) or at least non-significantly increased (Kranzfelder et al.,
2011; Urschel et al., 2003) postoperative in-hospital mortality.
On the other hand, evidence for CRT as a curative intent (definitive CRT: dCRT) has been
established for patients with esophageal cancer who otherwise do not qualify for surgery due
to disease extent and/or medical comorbidity. In Japan, dCRT for T4/M1(lymph) squamous
cell cancer (SCC) achieved 1-, 2-, and 3-year SRs of 41%, 27-32%, and 22-23%, respectively,
which compared well with SRs of T4 SCC undergoing resection (Ishida, et al., 2004; Japanese
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Society of Esophageal Diseases, 2005; Y Nishimura et al., 2002; Ohtsu, et al., 1999; Kumekawa
et al., 2006) [Table 1], although they were not a nonrandomized comparison. Subsequently,
three pivotal RCTs demonstrated that survival results were similar between dCRT and
neoadjuvant CRT followed by surgery or surgery only. A German trial revealed that dCRT
with at least 65Gy for T3-4/N0-1/M0 SCC offered similar survival results with less likelihood
of treatment-related mortality as compared with neoadjuvant CRT with 40Gy radiation (Stahl,
et al., 2005). A French FFCD trial recruiting T3/N0-1/M0 SCC patients found no benefit of
subsequent surgery following CRT for those responding to CRT (Bedenne et al., 2007). This
study has established a rationale that the response to neoadjuvant CRT is a favorable prog‐
nostic sign which allows the selection of patients most likely to benefit from dCRT, thereby
indicating the potential of dCRT for organ-sparing treatments. A CURE trial conducted in
China compared T2-3/N1 SCC patients undergoing standard esophagectomy with those
undergoing dCRT with 50-60Gy radiation and observed no survival differences between these
two treatments (Chiu et al., 2005). Consequently, a very recent meta-analysis has also eluci‐
dated that there is no trend regarding differences in overall survival between surgery and
dCRT (Pöttgen et al., 2012).
Author Tumorstage
Radiation
dose Chemotherapy Histology
Number
of
patients
Complete
response
rate
Median
survival
time
(months)
Survival
Tretment-
related
death
Ohtsu, 1999 T4 and/orM1 lymph 60 Gy
Fluorouracil
Cisplatin SCC 54 33% 9
1YSR=41%
3YSR=23% 6.8%
Nishimura,
2002
T4 N0-1
M0-1 60 Gy
Fluorouracil
Cisplatin SCC 28 32%
stage
III=12
stage
IV=5
2YSR=27% NA
Ishida, 2004
(JCOG9516)
T4 and/or
M1 lymph 60 Gy
Fluorouracil
Cisplatin SCC 60 15% 10 2YSR=32% 1.7%
Kumekawa,
2006
T1-4 and
M1lymph 60 Gy
Fluorouracil
Cisplatin SCC 81 42% 14
1YSR=62%
3YSR=22% 11.8%
YSR; year survival rate
Table 1. Treatment results of definitive chemo-radiotherapy for far advanced esophageal cancer in Japan.
Against these backgrounds and considering that surgery for esophageal cancer is a formida‐
ble procedure with significant morbidity and mortality (as discussed in section3.1) which raises
concerns about its applicability in most patients, dCRT, at first investigated with palliative
intent, has been further extended to resectable cases. While there was much initial enthusi‐
asm for dCRT, notes of caution have been raised in interpreting the accumulated dCRT
experience. These should be resolved for the further advancement of multimodal approaches
for esophageal cancer. This chapter introduces current problems to be taken into account when
performing dCRT, especially for patients with potentially resectable esophageal cancer.
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2. Definitive CRT for resectable esophageal cancer is promising and could
be an alternative to esophagectomy
Many chemotherapeutic agents are potential candidates that could be combined with radiation
(Kleinberg et al., 2007). Among these, the most frequently used agents are fluorouracil and
cisplatin, both act as radiosensitizers. Fluorouracil inhibits DNA and RNA synthesis resulting
in decreasing radiation-induced DNA injury repair, which eventually enhances radiation-
induced cytotoxicity. Cisplatin forms inter- and intrastrand cross-links to DNA that impede
repair. This action also leads to decrease in cellular repair in response to radiation-induced
damage. Therefore, besides a direct action of fluorouracil and cisplatin to DNA, these two
agents and radiation act synergistically.
Several nonrandomized comparisons have been conducted to investigate whether dCRT could
achieve the same impact on survival as esophagectomy for those patients deemed suitable for
surgery. More important are the encouraging results of dCRT for patients with operable rather
than inoperable esophageal cancer. Table 2 lists the results of dCRT for each stage of esophageal
cancer; these studies of dCRT with at least 60Gy radiation have shown consistent favorable
SRs, which compare favorably with the Japan nationwide 3-year SR (44%) of surgery only
(Japanese Society of Esophageal diseases, 2005). Ishikura et al. (Ishikura, et al., 2003) and
Hironaka et al. (Hironaka et al., 2003) respectively recruited T1-3 (70% T3) and T2-3 SCC
patients, and dCRT yielded 3-year and 5-year SRs of 49-55% and 46-49%, respectively. Three
other dCRT studies revealed promising 3-year SRs which were 80% for patients with stage II
SCC (Morota et al., 2009), 45% for those with stage II and III SCC (K Kato et al., 2011), and 72%
for those with stage 0-III SCC (Murakami et al., 1998). These results motivated the researchers
to conduct dCRT studies for less progressed esophageal SCC. For T1N0M0 stage I esophageal
SCC, dCRT resulted in 1-, 2-, 3-, 4-, and 5-year SRs of 98%, 93%, 79-89%, 81%, and 66-67%,
respectively, which could be compared favorably with survivals of surgical cases (H Kato et
al., 2009; Minashi et al., 2006; K Yamada et al., 2006; Yamamoto et al., 2011). These findings are
indeed encouraging and dCRT could be an alternative to esophagectomy. In addition, since
dCRT can preserve the esophagus, it could theoretically offer better posttreatment quality of
life than that for patients treated by surgery. Indeed, esophagectomy resulted in worse
functional, symptomatic, and global quality of life scores at 6 weeks postoperatively than
before surgery (Blazeby et al., 2000). However, the recently accumulated data on dCRT has
raised several issues of concern.
3. Problems remain to be resolved
3.1. Invasiveness of dCRT
When considering dCRT—especially for potentially resectable esophageal cancer, risks from
the treatment, i.e., treatment-related complications or death, should be taken into account in
evaluating whether dCRT could substitute for surgery. Some patients undergoing dCRT have
experienced severe grade 3/4 pericarditis, pleural effusion, and radiation pneumonitis, which
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respectively developed in 1.4-16% (Hironaka et al., 2003; Ishikura et al., 2003; K Kato et al.,
2011; Kumekawa et al., 2006; Minashi et al., 2006; Morota et al., 2009; Sasamoto et al., 2007),
1.4-14% (Hironaka et al., 2003;, Ishihara et al., 2010; Ishikura et al., 2003; K Kato et al., 2011;
Kumekawa et al., 2006; Li et al., 2010; Minashi et al., 2006; Morota et al., 2009; Sasamoto et al.,
2007), and 1.2-14% (Hironaka et al., 2003;, Ishihara et al., 2010; Ishikura et al., 2003; K Kato et
al., 2011; Kumekawa et al., 2006; Morota et al., 2009; Sai et al., 2004; Yamamoto et al., 2011;
Yamashita et al., 2008) of the study population. These complications eventually caused
Author Tumorstage
Radiation
dose Chemotherapy Histology
Number
of
patients
Complete
responders
(%)
Median
survival
time
(months)
Survival
Advanced cancer
Hironaka, 2003 T2-3 Nany M0 60Gy
Fluorouracil
Cisplatin SCC 53 37(70%) 33
3YSR=49%
5YSR=46%
Ishikura, 2003 T1-3,M0(70% T3) 60Gy
Fluorouracil
Cisplatin SCC 67 ND 44
3YSR=55%
5YSR=49%
Kato, 2011
(JCOG9906) II and III 60Gy
Fluorouracil
Cisplatin SCC 76 46(62%) 29
3YSR=45%
5YSR=37%
Morota, 2009 I-IVB 60Gy FluorouracilCisplatin SCC 69 36(52.2%) ND
stage I
3YSR=80%
stage II
3YSR=80%
stage III
3YSR=30%
stage IV
3YSR=30%
Murakami,
1998 0-III 60-75Gy
Fluorouracil
Cisplatin SCC 30 16(53.3%)
not
reached
2YSR=81%
3YSR=72%
T1 cancer
Kato, 2009
(JCOG9708) T1N0M0 30Gy
Fluorouracil
Cisplatin SCC 72 63(88%)
not
reached
2YSR=93%
4YSR=81%
Minashi, 2006 T1N0M0 60Gy FluorouracilCisplatin SCC 41 36(88%)
not
reached
1YSR=98%
3YSR=79%
5YSR=67%
Yamada, 2006 T1N0M0 55-66Gy FluorouracilCisplatin SCC 63 ND ND 5YSR=66%
Yamamoto,
2011 T1N0M0 60Gy
Fluorouracil
Cisplatin SCC 54 ND
not
reached
1YSR=98%
3YSR=89%
SCC; squamous cell cancer, YSR; year survival rate
ND; not described
Table 2. Treatment results of definitive chemo-radiotherapy for potentially resectable esophageal cancer.
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treatment-related death at a rate of 3-14% of the study population (K Kato et al., 2011; Morota
et al., 2009; Sai et al., 2004; Sasamoto et al., 2007; Yamashita et al., 2008) or 8-12% of the CR
patients (Ishihara et al., 2010; Ishikura et al., 2003; Kumekawa et al., 2006; Minashi et al.,
2006; Sasamoto et al., 2007) [Table 3]. Especially, 8% of treatment-related death among the CR
patients with stage I disease (Minashi et al., 2006) cannot be overlooked because they would
be expected to survive by surgery unless fatal complications occurred.
Author
Grade 3/4 Toxicities Tretment-related death
Pericarditis Pleural effusion Pneumonitis of all patients of CR patients
Hironaka, 2003 10.8%* 13.5%* 8.1%* 0.0% ND
Ishihara, 2010 NA 0.9%** 2.7%** ND 8.2%
Ishikura, 2003 5.8% 5.8% 2.2% ND 10.3%
Kato, 2011 (JCOG9906) 16.0% 9.0% 4.0% 5.3% ND
Kumekawa, 2006 3.7% 3.7% 1.2% ND 11.8%
Li , 2010 NA 6.8% NA ND ND
Minashi, 2006 2.8%* 11.1%* 0.0% ND 8.3%
Morota, 2009 1.4% 1.4% 1.4% 2.9% ND
Sai, 2004 NA NA 13.8% 13.8% ND
Sasamoto, 2007 8.9% 8.9% NA 7.1% 7.1%
Yamamoto, 2011 0.0% 0.0% 3.7% ND ND
Yamashita, 2008 NA NA 6.1% 6.1% ND
*among the complete responders, **death rate
ND; not described, CR; complete response
Table 3. Mortality and late morbidity of definitive chemo-radiotherapy.
The heart is susceptible to radiation injury. Pericardial damage is most frequently mentioned,
but all structures of the heart are at risk. Mediastinal radiation causes inflammation and
progressive fibrosis of all of the structures of this organ. A worsening of clinical severity with
increased radiation volume has been suggested. The risk of pericarditis has been found to rise
with increased total dose and larger dose per fraction, reaching 3-fold and 2-fold greater
relative risks at total doses of 41 Gy or greater, or a dose per fraction of 3.0 Gy or greater,
respectively (Cosset et al., 1991). Another study also demonstrated that larger fraction size has
a significant relationship with the chance of pericarditis (Martel et al., 1998 ). These observa‐
tions suggest that dose effect as well as fractionation effect account for the increased risk of
pericarditis.
Radiation pneumonitis has been reported in patients who have undergone mediastinal
radiation therapy for various diseases. The risks of radiation pneumonitis rise when radio‐
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therapy is combined with chemotherapy (McDonald et al., 1995; M Yamada et al., 1998). The
risks of lung toxicity appear to be related to dose-volume parameters such as the irradiated
lung volume, mean lung dose (Hernando et al., 2001), total dose (Roach et al., 1995), daily
fraction dose (Roach et al., 1995), and number of daily fractions (Roach et al., 1995), —although
there are some inconsistencies (Allen et al., 2003). Similarly, the percentage of lungs receiving
a specified dose has also been reported to be a predictor of pneumonitis (Madani et al., 2007;
Tsujino et al., 2003).
The obstruction of cardiac and mediastinal lymphatic vessels due to radiation fibrosis has been
postulated as a possible etiology of radiation-induced pericardial and pleural effusions. As a
result, radiation-induced cardiac or lung disease is responsible for a certain fraction of death
not directly attributable to esophageal cancer itself in some patients who would survive if they
could have undergone surgery without complications. Although nonsurgical approaches are
appealing in trying to manage this difficult disease, it is a fact that there is a fine therapeutic
window because of the significant toxicities, and the toxicity may outweigh any potential
advantages.
If treatment-related morbidity and mortality of dCRT exceed those of surgery, the benefits of
dCRT may be cancelled. Therefore, the risk balance between dCRT and surgery should be
taken into account in consideration of dCRT; however, one should remember that the mor‐
bidity and mortality of esophagectomy differ considerably between countries. Surgical
mortality was 2-4% in Japan (Fujita et al., 2010; Suzuki et al., 2011; Tachimori et al., 2009), while
4.2-7.6% in Taiwan (Lin et al., 2006), 6% in Italy (Ruol et al., 2009), 4-13% in the Netherlands
(Steyerberg et al., 2006; Wouters et al., 2008), and 6-23% in the USA (Atkins et al., 2004; Bailey
et al., 2003; Birkmeyer et al., 2002; Dimick et al., 2005; Finks et al., 2011; Rentz et al., 2003),
suggesting that differences in surgical mortality between countries can be more than doubled
or quadrupled.
However, the risk comparison between dCRT and surgery should require considerations of
the hospital volume, surgeon volume, specialization, study period, and country, i.e., when and
where the studies of dCRT are conducted, as well as the number of esphagectomies that each
surgeon performs. With regard to hospital volume, even in the USA —where surgical mortality
is generally high, hospital mortality after esophagectomy varied from 23% for institutions
undertaking <2 cases per annum to 8% for those undertaking 20 or more cases per annum
(Birkmeyer et al., 2002). In Japan, the average mortality was 1.8% when >51 esophagectomies
per annum were undertaken, compared with 4.6% if 20 or fewer esophagectomies were
performed per annum (Suzuki et al., 2011). Fujita et al. (Fujita et al., 2010) and Kazui et al.
(Kazui et al., 2007) also reported a larger hospital volume with a lower 30-day or in-hospital
mortality rates. The same volume-outcome relationship was also observed in Taiwan (Lin et
al., 2006) and the Netherlands (Wouters et al., 2008). In addition, high volume surgeons
experienced a 4.2% mortality rate, which was one-quarter of that of low volume surgeons,
approaching the average in-hospital mortality in Japan (Migliore et al., 2007). Also in Japan,
risk of morbidity by low volume surgeons is twice that of high volume surgeons (Yasunaga et
al., 2009). Collectively, a larger experience of esophagectomies could significantly reduce the
30-day or in-hospital mortality from 18% to 5% (Metzger et al., 2004).
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The study period is also a determinant. Single institutions in the USA (Orringer et al., 2007) or
Italy (Ruol et al., 2009) experienced consistently decreased hospital mortality from 4% to 1%
(Orringer et al., 2007) or from 8.2% to 2.6% (Ruol et al., 2009). Taking into account the various
determinants of hospital mortality, the treatment-related death rates of 8-12% among CR
patients of dCRT are undoubtedly higher than those of surgical mortality in Japan, but equal
to or lower than in some countries. Considering the balance between the risks of dCRT and
those of surgery, dCRT is regarded as a risky treatment as compared with surgery in some
countries or in some institutions where surgery can be performed more safely.
3.2. Response evaluation is not necessarily perfect
The lack of any definitive diagnostic methods currently available for the response evaluation
after dCRT remain pressing issues following dCRT. Strikingly, some segments of patients who
underwent surgery following dCRT due to persistent disease proved to be complete respond‐
ers postoperatively. The rates of such seemingly unnecessary salvage surgery are 10-50%
(Ariga, et al., 2009; Beseth et al., 2000; Lim et al., 2003; Murakami et al., 1998; M Nishimura et
al., 2007; Tachimori et al., 2009; Wilson et al., 2002). On the other hand, clinically diagnosed
CR patients sometimes prove to have residual diseases and eventually exhibit relapse. The
rates of overall recurrence or local recurrence after CR are substantial, being respectively
19-67% and 14-40% (Di Fiore et al., 2006; Ishihara et al., 2010; Kumekawa et al., 2006; Minashi
et al., 2006; Morota et al., 2009; Murakami et al., 1998; Takeuchi et al., 2007; Tougeron et al.,
2008; Wilson et al., 2000) [Table 4], suggesting that patients whose tumor response is deemed
complete after dCRT could have residual diseases and that clinically CR is not always a reason
to preclude further additional treatment. Such local recurrence rates do not depend on the
initial tumor stage or depth. These discrepancies may be ascribed to the limitations of current
imaging methods.
There are several diagnostic tools for evaluating responses to CRT. Endoscopy is an easily
available means of investigation, but its accuracy is low as recurrent or residual tumors often
lie beneath the mucosa [Figure 1]. Negative endoscopy findings have sometimes included
microscopic foci of a residual tumor in the resected esophagus specimens. Moreover, the
differentiation between tumor and radiation changes is not easy. A false negative rate of 48%
for biopsy by endoscopy (Jones et al., 1997) suggests a poor correlation between endoscopic
findings and pathologic status.
Endoscopic ultrasonography (EUS) also cannot reliably distinguish a residual tumor from
postinflammatory changes, which is, on the other hand, a characteristic of the efficacy of dCRT.
Even in earlier reports demonstrating the efficacy of EUS, (Hirata et al., 1997; Willis et al.,
2002), it should be noted that a perfect discrimination between T0 and T1 tumors was not a
consideration) since a certain degree of remaining tumor (<50-70%) was considered an EUS-
based response, or a scattered or even a remaining degree of 1/3< viable cells was considered
a pathological response. Such a cut-off value is less useful for deciding the need for salvage
surgery following dCRT because only patients with no viable cells could theoretically be
escaped from salvage surgery. EUS T staging accuracy after neoadjuvant CRT was only 43%,
Definitive Chemo-Radiotherapy for Resectable Esophageal Cancer — Unresolved Problems Remain
http://dx.doi.org/10.5772/55501
207
Author Tumor stage Radiationdose Histology
Number of
patients
Complete
responders (%)
Overall
recurrence
rate after CR
Local
recurrence
rate after CR
Di Fiore,
2006 T1-4/N0-1/M0
50 Gy or 60
Gy SCC 116 86 (74.1%) ND 40%
Ishihara,
2010 I-IVA 60 Gy ND 173 110 (63.6%) 26% 12%
Kumekaw
a, 2006 T1-4 and M1lymph 60 Gy SCC 81 34(42.0%) ND 25%
Minashi,
2006 T1N0M0 60 Gy SCC 41 36(88%) 39% 14%
Morota,
2009 I-IVB 60 Gy SCC 69 36(52.2%) ND 17%
Murakami
, 1998 0-III 60-75 Gy SCC 30 16(53.3%) 19% ND
Takeuchi,
2007 II-III 60 Gy SCC 178 113 (63.5%) 36% ND
Tougeron
, 2008 I-IV 50-55 Gy SCC+ADC 109 63(58%) 52% 33%
Wilson,
2000 anyT, anyN, M0 50 Gy SCC+ADC 31 24 (77.4%) 67% 21%
SCC; squamous cell cancer. ADC; adenocarcinoma
ND; not described, CR; complete response
Table 4. Overall and local recurrence rates among CR patients undergoing dCRT.
Figure 1. Low and high magnifications of a patient who was considered CR after CRT. Histological specimens revealed
small foci of a residual tumor in the esophageal wall which could not be detected by endoscopically obtained biopsy
specimens preoperatively.
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a rate ascribed to significant fibrosis and inflammation caused by CRT (Isenberg et al., 1998).
Consequently, EUS had a tendency to overstage lower pathological T stages. On the other
hand, 79% of pathologically complete responders were diagnosed as having T+ disease
(Zuccaro et al., 1999). These T+ patients underwent immediate post CRT surgery, but this could
deem unnecessary because of pathological CR. Similarly, EUS could not detect microscopic
disease, while 27% of patients with positive EUS findings proved to have no residual tumor
in the resected specimens (Beseth et al., 2000). Furthermore, EUS may be suboptimal when the
sonography probe cannot pass the tumor.
Researchers have reported a low accuracy of CT for the assessment of responses in patients
with esophageal cancer; this accuracy was substantially worse than that of EUS and FDG-PET
(fluorine18-labelled deoxyglucose in positron emission tomography). This is most likely owing
to the difficulty in the differentiation between viable tumors and reactive changes, including
edema, fibrosis, and inflammation at CT. CT tumor volume change was poorly correlated with
pathological tumor response (Griffith et al., 1999). Some tumors exhibited marked volume
regression with a poor histological response, while some tumors showed little volume
regression with a considerable histological response. This means that CT by itself represents
an inadequate tool in assessing those who have residual disease and those who should undergo
surgery following CRT. Jones et al. reported the same results (Jones, et al., 1999).
On the other hand, PET is a useful noninvasive tool in discriminating responders from
nonresponders, with the colleration between PET-based response assessment and pathology
being 78% (Flamen et al., 2002). The sensitivity and specificity of PET ranged from 71-100%
and 55-95%, respectively (Brücher et al., 2001; Flamen et a., 2002; Weber et al., 2001). Any false
positive results are attributable to the metabolically active leukocytes or macrophages
associated with post CRT inflammation. False negative phenomena can occur because PET is
unable to detect perfectly the residual viable disease in the primary tumor.
3.3. Salvage surgery is highly invasive
Patients who have received dCRT should undergo subsequent surgery if the tumors exhibit
strictures or subsequent relapse. Salvage surgery is a surgery for residual or recurrent disease
following dCRT, but it is technically more difficult and highly invasive than primary surgery,
leading to increased morbidity (50-79%) and in-hospital mortality (7-22%) due to the adverse
events of predominantly respiratory complications and anastomotic leakage (Chao et al.,
2009; Nakamura et al., 2004; M. Nishimura et al., 2007; Oki et al., 2007; Smithers et al., 2007;
Swisher et al., 2002; Tachimori et al., 2009; Tomimaru et al., 2006). These complications are
attributable to the radiation-induced injury in the thoracic cavity that causes an increase in
bleeding, fibrotic masses around the tumor due to the fibrogenic pathway that makes surgical
technique more difficult, and an increasingly fragile stomach, esophagus, and trachea arising
from the impaired blood supply that eventually causes anastomotic leakage or conduit
necrosis. Even in Japan, these hospital mortality rates are obviously higher than those for
primary esophagectomy reported from specialized centers or in a nationwide survey (2-4%)
(Fujita et al., 2010; Suzuki et al., 2011; Tachimori et al., 2009). Reserving surgery for patients
not already cured by CRT should always be taken into account in performing dCRT, and efforts
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should be continuously made to reduce mortality and to select patients who stand to benefit
most from this invasive treatment.
First, invasiveness undoubtedly depends on surgical procedure. The most common surgical
approaches which are applicable to cancers of the upper, middle and lower esophagus are the
Ivor-Lewis or McKeown esophagectomy. The Ivor-Lewis esophagectomy involves right
thoracotomy with midline laparotomy and an anastomosis of the gastric conduit to the
proximal mediastinal esophagus (at or above the azygos vein). The McKeown technique
involves right thoracotomy, laparotomy, and cervical anastomosis, which facilitates precise
surgical staging and enables more local control (van de Ven et al., 1999). The extent of lym‐
phadenectomy is three-field (cervial thoracic, abdominal), which has traditionally been more
prevalent in Japan, measuring the prevalence of positive cervical nodes (Akiyama et al.,
1994; Nishihira et al., 1995). The survival benefit of three-field lymphadenectomy was suggeted
in Japanese (Nishihira et al., 1998) and Western series (Altorki et al., 2002). Importantly, the
risks of positive cervical nodes are substantial even at an earlier stage (Stein et al., 2005), and
are seemingly independent of histological types (SCC or adenocarcinoma) or independent of
tumor location within the esophagus (Akiyama et al., 1994; van de Ven et al., 1999). The
McKeown technique enables this dissection to be performed under direct vision, allowing
more precise dissection in cases where the tumor is large, lymphadenopathy is present, or the
tumor is located in proximity to the airway (upper or middle thoracic esophagus). However,
in salvage surgery, attempts have been made to reduce surgical morbidity and mortality with
preservation of the blood supply to the trachea or to the main bronchus as well as to the
reconstruction conduit. These include a reduced scope of lymphadenectomy with avoidance
of cervical lymph node dissection or the preservation of right and left bronchial arteries
(Tachimori et al., 2009).
Second, an accurate prediction of resection status prior to surgery is important at the time of
completion of dCRT since resection status is one of the significant factors that affect survival
after salvage surgery. Long term survivors after salvage surgery were those undergoing R0
resection, while no patients left with gross or microscopic residual tumors after salvage surgery
(R1/R2 resections) survived more than 24 months in any series (Chao et al., 2009; Nakamura
et al., 2004; Oki et al., 2007; Swisher et al., 2002; Tachimori et al., 2009; Tomimaru et al., 2006).
Multivariate analysis also confirmed resection status correlation with patient survival (Chao
et al., 2009; Tomimaru et al., 2006). However, the resection status cannot be confidently
predicted before surgery or even during surgery because of the indistinct planes between a
tumor and fibrotic masses within the irradiated mediastinum. In this regard, PET, which has
a relatively high specificity, could identify non-responders for dCRT and may be a more useful
imaging modality than CT or EUS (Swisher et al., 2004) to select patients who are absolutely
unfit for salvage surgery, allowing for early modifications of the treatment strategy of such
selected patients.
Third, it is imaginable that larger, more advanced cancers are more difficult to control than
smaller ones and require longer doses of RT; however, higher radiation doses are associated
with increased morbidity. A dose of 60Gy of radiation has been used for dCRT in Japan (Kenjo
et al., 2009). In this regard, the possibility of reducing total radiation volume from 64.8Gy to
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50.4Gy (Minsky et al., 2002; Nakajima et al., 2009) has recently prompted a phase II study of
dCRT with a radiation dose of 50.4Gy for stage II/III esophageal SCC (JCOG0909).
4. Future perspectives
The combination of conventional CRT with molecular targeting therapies has been developing.
This combination is encouraged by the findings that radiotherapy plus cetuximab, a mono‐
clonal antibody against epidermal growth factor receptor, for loco-regionally advanced SCC
of the head and neck resulted in the prolonged duration of loco-regional control, progression
free survival, and overall survival as compared with radiotherapy alone (Bonner et al., 2006;
Bonner et al., 2010). The feasibility of adding cetuximab to CRT for esophageal cancer is
supported by the safety profiles of this combination without any increase in esophagitis or
other radiation-enhanced toxicity (Safran et al., 2008). The ongoing phase III trials (NCT
00655876, NCT01107639, NCT00509561) will provide evidence whether cetuximab in combi‐
nation with CRT is effective in locally advanced or resectable esophageal cancer (http://
clinicaltrials.gov).
A gain in survival with a substantial increase in toxicity necessitates considerable caution that
immediately draws the attention of clinicians. Diagnostic tools which can accurately evaluate
tumor response early in the course of dCRT can facilitate decisions about whether this toxic
therapy should be continued in responders, or stopped in non-responders. However, there are
currently no modalities that can definitively confirm CR. The reason for this problem is that
the tools to estimate individual patient prognosis or tumor response are unreliable, and a
diagnosis of CR is possibly merely by resected specimens. This means that negative findings
by these imaging methods do not rule out residual disease. Clearly, patients with residual
disease would no longer be long term survivors without undergoing resection. Therefore,
efforts should continue to establish diagnostic tools for the detection of residual diseases after
CRT.
One challenge in this regard lies in the detection of histologic markers—such as p53, Ki67, and
EGF-R—for the prediction of therapeutic response; however, neither a single marker nor a
combination of markers can correctly be used to predict the response with sufficient accuracy.
The small number of patients or small number of genes investigated in this field is a further
limitation. In the future, gene profiling may help identify markers that can be used in combi‐
nation with conventional imaging methods for the prediction of the response to dCRT.
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